• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Patient Encourages Others to ‘Continue Living’ After a Myeloma Diagnosis By Advocating

by | Mar 2, 2022 | Uncategorized

Source: Cure Today articles As part of its Speaking Out video series, CURE spoke with Throwing Bones founder, Kenny Caps, about raising awareness for multiple myeloma, and why sharing one’s story is helpful for others. Read More

FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma

by | Mar 1, 2022 | Uncategorized

Source: Healio News The FDA approved ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.The indication applies to patients who received four or more previous lines of therapy,...

FDA Approves Carvykti, a CAR T-Cell Therapy, for Pretreated Relapsed/Refractory Myeloma

by | Mar 1, 2022 | Uncategorized

Source: Cure Today articles Ninety-eight percent of patients with pretreated relapsed/refractory myeloma responded to treatment with Carvykti, a newly approved CAR T-cell therapy for this patient population. Read More

#ASCO20 Virtual Scientific Program: Dr. John Sweetenham Highlights Key Abstracts on Hematologic Malignancies

by | Feb 22, 2022 | Uncategorized

Source: ASCO Daily News In today’s episode, Dr. John Sweetenham, Editor-in-Chief of ASCO Daily News and associate director for Clinical Affairs at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, discusses key abstracts on...

Dr. James L. Gulley Discusses Scientific Highlights From #ImmunoOnc20

by | Feb 22, 2022 | Uncategorized

Source: ASCO Daily News In this episode, Dr. James Gulley, chief of the Genitourinary Malignancies Branch and the Immunotherapy group at the National Cancer Institute at NIH, shares highlights from the ASCO-SITC Immuno-Oncology Symposium.   Transcript ASCO Daily News:...

Dr. Derek Raghavan on Challenges Facing the Oncology Community in 2021

by | Feb 22, 2022 | Uncategorized

Source: ASCO Daily News In today’s episode, we hear from the internationally renowned medical oncologist and researcher, Dr. Derek Raghavan, president of the Levine Cancer Institute. He reflects on the extraordinary events of 2020 amid the COVID-19 pandemic and...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT